TEVA - Teva Pharmaceutical Industries Limited

NYSE - NYSE Delayed Price. Currency in USD
24.22
+0.11 (+0.46%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close24.11
Open24.17
Bid24.20 x 2200
Ask24.30 x 800
Day's Range23.45 - 24.37
52 Week Range10.85 - 25.14
Volume16,476,663
Avg. Volume10,472,323
Market Cap24.663B
Beta1.11
PE Ratio (TTM)N/A
EPS (TTM)-15.79
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2017-11-27
1y Target Est21.09
Trade prices are not sourced from all markets
  • Teva’s generic EpiPen approved in the U.S., with perfect timing
    MarketWatch4 hours ago

    Teva’s generic EpiPen approved in the U.S., with perfect timing

    The U.S. has had monthslong shortages of Mylan’s EpiPen and other products, causing parents to worry as back-to-school season approaches.

  • EpiPen Shortage 2018: 13 Things for Parents to Know
    InvestorPlaceyesterday

    EpiPen Shortage 2018: 13 Things for Parents to Know

    Here are a few things to know about the EpiPen shortage. The U.S. Food and Drug Administration has confirmed that there is in fact a shortage of EpiPens. The shortage has actually been going on for months, but is only kick up more dust lately as school starts.

  • Why the FDA's generic EpiPen approval is a big win for a N.J. company
    American City Business Journalsyesterday

    Why the FDA's generic EpiPen approval is a big win for a N.J. company

    Teva received FDA approval of a generic version of Mylan's EpiPen, but it didn't make the device. Here's who did.

  • Lifesaving EpiPen Device Still Out of Stock at Many Pharmacies
    Bloombergyesterday

    Lifesaving EpiPen Device Still Out of Stock at Many Pharmacies

    Mylan NV’s EpiPen is still hard to find at many pharmacies, three months after U.S. authorities declared that the lifesaving allergy device was in shortage, a survey by Wells Fargo & Co. showed. The finding comes a day after Teva Pharmaceutical Industries Ltd. gained Food and Drug Administration approval to sell a generic version of Mylan’s epinephrine autoinjector. Wells Fargo analysts reached out to 53 pharmacies across the country on Thursday and found that 66 percent were out of stock of Mylan’s EpiPens, not including EpiPen Jr., analyst Davis Maris said in a note Friday.

  • Mylan Suffers a Blow as Teva Gets FDA Nod for EpiPen Generic
    Zacksyesterday

    Mylan Suffers a Blow as Teva Gets FDA Nod for EpiPen Generic

    Mylan (MYL) suffers another setback as Teva wins the FDA approval of first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector for the emergency treatment of allergic reactions.

  • Teva Gets FDA Nod for First Generic Version of Mylan's EpiPen
    Zacksyesterday

    Teva Gets FDA Nod for First Generic Version of Mylan's EpiPen

    Teva (TEVA) gains FDA approval for the first generic version of Mylan's (MYL) popular EpiPen (epinephrine) auto-injector for severe allergy treatment.

  • Mylan’s Q2 Profit Fell against Backdrop of US Market Dynamics
    Market Realistyesterday

    Mylan’s Q2 Profit Fell against Backdrop of US Market Dynamics

    Mylan reported its second-quarter results on August 8. Mylan had completed a $1.0 billion share repurchase program at the beginning of 2018, the benefits of which are reflected in its adjusted EPS growth. In the second quarter, Mylan’s gross profit fell ~40% YoY to $962.5 million.

  • Regeneron, Teva Announce Positive Data on Osteoarthritis Drug
    Zacksyesterday

    Regeneron, Teva Announce Positive Data on Osteoarthritis Drug

    Regeneron (REGN) along with partner Teva announces positive top-line results from a late-stage candidate on fasinumab in patients with chronic pain from osteoarthritis of the knee or hip.

  • Benzingayesterday

    The Daily Biotech Pulse: Aveo Slips On Stock Offering, FDA Greenlights Generic EpiPen, Pfenex Exec Resigns

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 16) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) Eli Lilly And ...

  • ACCESSWIREyesterday

    Today’s Research Reports on Stocks to Watch: Teva Pharmaceutical and Mylan

    NEW YORK, NY / ACCESSWIRE / August 17, 2018 / Shares of Teva jumped on Thursday after gaining FDA approval for its generic version of the EpiPen and announcing positive data results on its Fasinumab drug ...

  • If I Had to Buy 1 Stock in August, It Would Be This One
    Motley Foolyesterday

    If I Had to Buy 1 Stock in August, It Would Be This One

    This healthcare company appears poised to turn a corner.

  • Financial Timesyesterday

    [$$] FirstFT: Today’s top stories

    Whistleblower protections at Royal Bank of Canada are under scrutiny. The UK’s Financial Conduct Authority is investigating after a former trader at Canada’s biggest bank won his case for unfair dismissal and at least five more potentially similar cases came to light. The London-based RBC staff involved claim to have been dismissed without due process after highlighting legal and compliance problems across a range of businesses in cases spanning several years, multiple people familiar with the matter told the Financial Times.

  • Business + Coffee: Google employee protest, Teva generic EpiPen, Trump NFL sentiment
    Yahoo Finance Video22 hours ago

    Business + Coffee: Google employee protest, Teva generic EpiPen, Trump NFL sentiment

    Friday, August 17: Google employees sign protest letter over Google working on a censored version of Google in China; Teva gets FDA approval for generic EpiPen right after Buffett doubled his stake; Yahoo Finance survey results on sentiment about Trump and NFL protests. Yahoo Finance’s Dan Roberts delivers the news before your weekend.

  • The FDA Finally Approves Generic EpiPen That May Be Cheaper
    Meredith Videosyesterday

    The FDA Finally Approves Generic EpiPen That May Be Cheaper

    Manufactured by Teva Pharmaceuticals.